ROCHE HOLDING $65.96

up +0.40


24/5/2013 04:24 PM  |  OTC : RHHBY  |  Industries : Manufacturing / Pharmaceutical and Medicine Manufacturing
12 Mo. Price Change : 64% - RHHBY has outperformed the S&P 500 by 39%

Get Trend Analysis Icon Get Trend Analysis

Partner Headlines

  1. Allergan Reports Mixed Q4, But Bullish Margin Outlook

    Investors Business Daily

  2. Roche 2012 Net Profit Rises 2%

    Benzinga

  3. Biogen, Illumina Ready Q4 Reports As Stocks Struggle

    Investors Business Daily

  4. Life Technologies Stock Hits High On Buyout Rumors

    Investors Business Daily

  5. Will the Flu Season Make Your Portfolio Sick?

    Benzinga

  6. Eylea Sales Hurt Regeneron

    Investors Business Daily

  7. Regeneron Shares Fall After Sales Of Eye Drug Posted

    Investors Business Daily

  8. Illumina plunges as talks falter

    Investors Business Daily

  9. Benzinga's M&A Chatter for Monday January 7, 2013

    Benzinga

  10. Illumina Stock Falls As Roche Says Buyout Talks Fail

    Investors Business Daily

  11. Roche eyes Illumina purchase

    Investors Business Daily

  12. Illumina Stock Leaps On Roche Acquisition Reports

    Investors Business Daily

  13. For The Record

    Investors Business Daily

  14. Foreign Drugmakers Holding Up, But Some Have Flaws

    Investors Business Daily

  15. Amgen Buying DeCode Genetics To Find Targeted Drugs

    Investors Business Daily

  16. Halozyme Announces Roche Filing to European Medicines Agency ...

    Benzinga

  17. Illumina Starring In Multiple Merger Dramas; Stock Up

    Investors Business Daily

  18. Stem Cell Research Gets Boost From New Cell Bank

    Investors Business Daily

  19. A Peek Into The Market Before The Trading Starts

    Benzinga

  20. Curis Announces Worldwide Licensing Rights for IAP Inhibitor ...

    Benzinga

  21. Illumina Stock Falls As Analyst Warns Of Competition

    Investors Business Daily

  22. Benzinga's M&A Chatter for Friday November 23, 2012

    Benzinga

  23. Abraxane Cancer Trials Help Justify Celgene Buyout

    Investors Business Daily

  24. Benzinga's M&A Chatter for Wednesday November 7, 2012

    Benzinga

  25. Amgen Cholesterol-Fighter Shows Promise, Shares Rise

    Investors Business Daily

  26. Watson Pharma Starts New Era As Generic Drug Titan

    Investors Business Daily

  27. Roche's cancer fighters rise

    Investors Business Daily

  28. 52-Week High Companies: PRGO, NOC, RHHBY, NXY, PFE

    GuruFocus

  29. Seattle Genetics Will Get Undisclosed Milestone Payments

    Benzinga

  30. Benzinga's M&A Chatter for Tuesday October 2, 2012

    Benzinga

  31. Stocks Open Firm, Slip, End Mixed With Weak Volume

    Investors Business Daily

  32. Celgene Melanoma Drug Test Positive; Stock Rises

    Investors Business Daily

  33. Stocks Up In Quiet Trade; Illumina, Valspar Rising

    Investors Business Daily

  34. Race For Next Hepatitis C Drug Gets Tighter

    Investors Business Daily

  35. Benzinga's M&A Chatter for Tuesday September 18, 2012:

    Benzinga

  36. Roche Receives FDA Clearance for Herpes Tests

    Benzinga

  37. AstraZeneca Appoints Pascal Soriot As New CEO

    Benzinga

  38. How To Invest: Big Winners Often Sport High P-Es

    Investors Business Daily

  39. Myriad Genetics Patents Upheld, But Fight Not Over

    Investors Business Daily

  40. Myriad Genetics Earnings Expected To Stay On Rebound

    Investors Business Daily

  41. FDA Approves Lucentis (Ranibizumab Injection) for Treatment of ...

    Benzinga

  42. Benzinga'a M&A Chatter for Friday August 3, 2012

    Benzinga

  43. Stocks Jump On Jobs Data, ECB Hopes

    Investors Business Daily

  44. Big Corn, Big Data Helps Deliver Big Gains On IBD 50

    Investors Business Daily

  45. Stocks Leap In Weaker Trade; Cabela's, Cirrus Hit New Highs

    Investors Business Daily

  46. Stocks Jump In Lower Volume; Alexion, Teradata Gain

    Investors Business Daily

  47. Jobs, Europe Spark Early Rally; Polaris Surges

    Investors Business Daily

  48. Edwards Owens Buys Green Mountain Coffee and Allscripts, Adds to ...

    GuruFocus

  49. Regeneron Forms Cup-Type Base, Possible 145.14 Entry

    Investors Business Daily

  50. Sales Of Januvia And Gardasil Boost Merck's Earnings

    Investors Business Daily

  51. FDA Clears Roche's Vitamin D laboratory Test

    Benzinga

  52. Roche Cutting 1,000 U.S. Jobs In R&D Downsizing

    Investors Business Daily

  53. Arena Down In Massive Volume After Bank Downgrade

    Investors Business Daily

  54. Big Pharmas Gamble On Risky Alzheimer's Treatments

    Investors Business Daily

  55. Roche Submits TnT-hs Assay to FDA for Clearance on the Cobas ...

    Benzinga

  56. Abbott's Humira test positive

    Investors Business Daily

  57. Abbott, Roche Issue Dueling Arthritis Drug Reports

    Investors Business Daily

  58. From Yesterday, Genentech Data Showed That People With Metastatic ...

    Benzinga

  59. Drug Stocks In The Spotlight At Cancer Conference

    Investors Business Daily

  60. Facebook IPO: Crunching The Data Behind The Hype

    Investors Business Daily

  61. From Earlier: Genentech Reports Positive Study of ACTEMRA Given by ...

    Benzinga

  62. Regeneron Posts First-Ever Profit, Lifts Guidance

    at IBD

  63. Apple Likely To Maintain iPhone Pricing, Subsidies

    at IBD

  64. Top 5 Key Takeaways From Apple's Blowout Q2 Report

    at IBD

  65. Buyout Chatter Puts Watson Pharma In The Spotlight

    at IBD

  66. Illumina again rejects Roche

    at IBD

  67. Illumina Investors Reject Roche, Which Will Walk

    at IBD

  68. Illumina

    at IBD

  69. Illumina (ILMN) Loses 2.1% after Roche Insists Current Bid is Adequate

    At Market Intelligence Center

  70. Illumina Falls As Roche Doesn't Raise $6.5 Bil Offer

    at IBD

  71. Roche Ups Bid For Illumina 15% To $51 A Share

    at IBD

  72. Jobs Data Trip Stock Futures; Red Hat, Illumina Gain

    at IBD

  73. Roche cuts Indian drug prices

    at IBD

  74. Roche To Sell Blockbuster Cancer Drugs Cheap In India

    at IBD

  75. Roche touts bid for Illumina

    at IBD

  76. Roche

    at IBD

  77. Halozyme Q4 results fall short

    at IBD

  78. A Peek Into The Market Before The Trading Starts

    at Benzinga

  79. Financial Breakfast: Morning News Summary for March 1, 2012

    at Benzinga

  80. Roche's Ventana Receives FDA Approval of INFORM HER2 Dual ISH ...

    at Benzinga

  81. From Earlier: Illumina Comments on Roche's Unsolicited Tender ...

    at Benzinga

  82. From Earlier: Roche Extends Tender Offer for Illumina

    at Benzinga

  83. Benzinga's M&A Chatter for Tuesday February 21, 2012

    at Benzinga

  84. Regeneron Nearly Doubles Forecast On Eye Drug Sales

    at IBD

  85. Benzinga's M&A Chatter for Thursday February 9, 2012

    at Benzinga

  86. From Earlier: Roche Disappointed by the Actions of Illumina's ...

    at Benzinga

  87. GlaxoSmithKline Swings To Profit But Shy Of Estimates

    at IBD

  88. Roche Announces FDA Approves Erivedge Capsule, the First Medicine ...

    at Benzinga

  89. Investing Mistakes and What Not to Do (End 2009-Mid 2010)

    at GuruFocus

  90. Benzinga's M&A Chatter for Friday January 27, 2012

    at Benzinga

  91. Gilead, Celgene Join Big Pharma On M&A Front

    at IBD

  92. Benzinga's M&A Chatter for Thursday January 26, 2012

    at Benzinga

  93. Roche Responds to Illumina Board, Says Confident Holders Will See ...

    at Benzinga

  94. Illumina's "Poison Pill" Against Roche's Hostile Takeover Might ...

    at GuruFocus

  95. Benzinga's M&A Chatter for Wednesday January 25, 2012

    at Benzinga

  96. Stock Market Climbs After Fed Policy News

    at IBD

  97. Stocks Mixed As Apple Climbs Following Earnings

    at IBD

  98. Pacific Biosciences of California Surging after Roche's Hostile ...

    at Benzinga

  99. Biotechs Cut Biosimilar Deals As FDA Carves Path

    at IBD

  100. Bristol-Myers, AstraZeneca Diabetes Drug Delayed

    at IBD
People viewing RHHBY also viewed: , , , , , ,
Marketplace
Trading Center